Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Pharmacyclics"
Count: 116
Selected: 0
| NCT ID | Title |
|---|
| NCT02599324 | Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors | ||
| NCT03112174 | Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) | ||
| NCT02947347 | Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma | ||
| NCT02582879 | informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia | ||
| NCT03790332 | Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD) | ||
| NCT01724346 | Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | ||
| NCT02959944 | Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD) | ||
| NCT02910583 | Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) | ||
| NCT02077166 | Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | ||
| NCT01962792 | Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma | ||
| NCT02165397 | Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia | ||
| NCT02436668 | Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) | ||
| NCT02264574 | A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | ||
| NCT01109069 | Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia | ||
| NCT01478581 | Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma | ||
| NCT01578707 | A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | ||
| NCT02548962 | Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma | ||
| NCT01980628 | Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma | ||
| NCT02195869 | Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease | ||
| NCT02401048 | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas | ||
| NCT01980654 | Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma | ||
| NCT02142049 | Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma | ||
| NCT02403271 | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | ||
| NCT03229200 | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | ||
| NCT02351037 | Study of Ibrutinib in Subjects With Acute Myeloid Leukemia | ||
| NCT01722487 | Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL | ||
| NCT01325701 | Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma | ||
| NCT01744691 | A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion | ||
| NCT02902965 | Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma | ||
| NCT01236391 | Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL) | ||
| NCT01217749 | Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL | ||
| NCT01292135 | Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL) | ||
| NCT00373204 | Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere) | ||
| NCT00076401 | A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL) | ||
| NCT00100711 | Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | ||
| NCT00121420 | Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases | ||
| NCT01020006 | Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine | ||
| NCT00724984 | Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma | ||
| NCT01105247 | Safety of PCI-32765 in Chronic Lymphocytic Leukemia | ||
| NCT00365183 | Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer | ||
| NCT00003563 | Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases | ||
| NCT01149668 | A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer | ||
| NCT00849654 | Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma | ||
| NCT00562224 | Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients | ||
| NCT00473577 | Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients | ||
| NCT00120939 | Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer | ||
| NCT00102505 | A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC) | ||
| NCT00080054 | A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas | ||
| NCT00290004 | Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | ||
| NCT00129844 | Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer |
